Updated:
Standard BioTools
Standard BioTools, the post-Fluidigm entity formed in 2022, sells mass cytometry and spatial biology instruments to academic and biopharma labs.
Standard BioTools
Standard BioTools was born from a fundamental corporate reset. In 2022, the former Fluidigm Corporation — a struggling Bay Area life-science tools company — merged with proteomics leader Olink and immediately adopted the Standard BioTools name, with Fluidigm's longtime executive Michael Egholm assuming the CEO role. The combination was engineered by an activist investor, Casdin Capital, which pushed to shed Fluidigm's legacy microfluidics business and concentrate the enterprise around the higher-growth mass cytometry and spatial biology platforms the company had been developing since acquiring DVS Sciences in 2014. The firm is publicly listed on Nasdaq under the ticker LAB. The company's core is its CyTOF mass cytometry technology, which uses metal-tagged antibodies to measure dozens of protein markers simultaneously in single cells — a material throughput advantage over fluorescence-based flow cytometry. The Hyperion Imaging System extends this into tissue sections, mapping 40-plus protein markers at subcellular resolution. Standard BioTools sells its instruments to academic core labs, contract research organizations, and large pharmaceutical firms. In 2023, the company disclosed that over 1,200 peer-reviewed publications had cited CyTOF or Hyperion, reflecting adoption among immunology, oncology, and infectious disease researchers. The firm competes head-to-head with Akoya Biosciences in the spatial biology category and with Becton Dickinson in the broader flow cytometry market. Standard BioTools employs several hundred people, largely split between its South San Francisco headquarters and a Toronto-area office that houses much of its R&D and instrument manufacturing. Headcount has been reduced from Fluidigm's pre-pandemic peak as the company streamlined around its mass cytometry platforms. In August 2023, Standard BioTools sold its legacy microfluidics genomics business to Singapore-based biotech firm SPT Labtech, completing the exit from the product lines that defined the company under the Fluidigm name. This deal sharpened the firm's focus on a pure-play spatial biology and single-cell proteomics portfolio. Standard BioTools holds a genuinely unusual position in the public life-science tools market: it is a mid-cap, single-platform company in an industry dominated by diversified giants like Thermo Fisher and Danaher. Its moat is installed base — the consumables and antibodies that Helios and Hyperion customers must buy repeatedly create a replacement cycle that makes switching costs high. The Casdin-backed recapitalization and name change reflect an investor thesis that the CyTOF platform, properly managed and stripped of distraction, can generate the kind of recurring revenue multiples the market grants to best-in-class tools businesses.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Principals
Michael Egholm
Chief Executive Officer
Sector focus
Frequently asked questions
What is the relationship between Standard BioTools and Fluidigm?
Standard BioTools IS Fluidigm, effectively. In 2022, Fluidigm Corporation merged with Olink's proteomics assets and adopted the Standard BioTools name. The legacy Fluidigm microfluidics business was sold to SPT Labtech in 2023, so Standard BioTools now represents exclusively the mass cytometry and tissue imaging platforms that Fluidigm had built over the prior decade.
Who actually controls Standard BioTools?
Standard BioTools is a publicly traded company (Nasdaq: LAB) with no single controlling shareholder. Activist investor Casdin Capital engineered the 2022 merger and board reconfiguration that created the current entity. Casdin partner Eli Casdin sits on the board, and the firm's influence shaped the decision to divest microfluidics and concentrate the company around CyTOF and Hyperion.
How does mass cytometry differ from traditional flow cytometry?
Standard BioTools' CyTOF platform uses metal-isotope-tagged antibodies detected by time-of-flight mass spectrometry, rather than fluorophore-tagged antibodies detected by lasers. This eliminates spectral overlap — the fundamental bottleneck in fluorescence flow cytometry — and allows researchers to measure 40-plus protein markers simultaneously on a single cell. The tradeoff is slower acquisition speed and lower cell-throughput per second.
What does the consumables revenue stream look like for Standard BioTools?
Standard BioTools sells its Helios and Hyperion instruments at relatively thin margins. The durable revenue comes from the proprietary metal-conjugated antibodies, assay kits, and service contracts that instrument owners must purchase continuously. This razor-and-blades model means installed base growth is the leading indicator of future revenue, and the company reports instrument placements and consumables pull-through as its core operational metrics.
Is Standard BioTools considered a takeover target?
Standard BioTools' market capitalization, typically in the low hundreds of millions, makes it absorbable by any major life-science tools consolidator. However, the company's post-2022 restructuring — engineered by an activist with a clear value-creation thesis — suggests near-term focus is on independent execution. Casdin Capital's board presence signals an intention to build an independent spatial biology pure-play, not preview a sale.
How does Standard BioTools compare to Akoya Biosciences in spatial biology?
Both companies sell instruments that map protein expression in tissue sections, but the underlying technology differs. Standard BioTools' Hyperion uses mass-cytometry detection, measuring 40-plus protein markers with no spectral overlap. Akoya's PhenoCycler uses fluorescence-based barcoding and can detect a larger number of protein targets per tissue section. Hyperion is generally regarded as simpler to operate but lower-plex than Akoya's high-end offerings.
What happened to the Olink proteomics business after the merger?
The 2022 merger that created Standard BioTools separated Olink's proteomics business from the company's mass cytometry operations. Olink's Proximity Extension Assay platform — which measures protein biomarkers with high sensitivity — continues to operate independently and is not part of Standard BioTools. The combined entity retained the mass cytometry assets while Olink's assays business was established as a standalone company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: